2021
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2008
Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response
Kenney B, Tormey CA. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets 2008, 19: 379-383. PMID: 18791945, DOI: 10.1080/09537100802082280.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAmputation, SurgicalAnti-Bacterial AgentsAntigens, Human PlateletAutoantibodiesBacteremiaCeftazidimeDrug Therapy, CombinationFoot DiseasesGram-Positive Bacterial InfectionsHumansImmunoglobulin GImmunoglobulin MImmunologic MemoryMaleMiddle AgedPurpura, Thrombocytopenic, IdiopathicSurgical Wound InfectionVancomycinConceptsAntibiotic therapyPlatelet antibodiesPlatelet countPlatelet destructionAdverse bleeding eventsAnamnestic antibody responseDrug-related thrombocytopeniaNew onset thrombocytopeniaRapid platelet destructionAnti-platelet antibodiesNormal platelet countCases of thrombocytopeniaSafe drug useBleeding eventsVancomycin administrationWet gangreneImmune thrombocytopeniaImmediate discontinuationRare complicationMale patientsAnamnestic responseDrug withdrawalSevere thrombocytopeniaAcute reductionPrior sensitization